A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis
一项 IIb 期、开放标签、随机对照、剂量范围多中心试验，旨在评估不同剂量的德尔帕唑利联合贝达喹啉、德拉马尼和莫西沙星治疗新诊断的、无并发症的、涂片阳性、药物敏感性肺结核成年患者的安全性、耐受性、药代动力学和暴露-反应关系。
期刊:Trials
影响因子:2
doi:10.1186/s13063-023-07354-5
Dierig, A; Hoelscher, M; Schultz, S; Hoffmann, L; Jarchow-MacDonald, A; Svensson, E M; Te Brake, L; Aarnoutse, R; Boeree, M; McHugh, T D; Wildner, L M; Gong, X; Phillips, Ppj; Minja, L T; Ntinginya, N; Mpagama, S; Liyoyo, A; Wallis, R S; Sebe, M; Mhimbira, F A; Mbeya, B; Rassool, M; Geiter, L; Cho, Y L; Heinrich, N
